This study highlights the potential of the NKG2A nanoantibody in overcoming the immunosuppressive effects of melanoma by activating natural killer (NK) and CD8+ T cells in both mice and humans, thereby enhancing the immune response against tumor cells. This evidence concerns the gene KLRC1 and melanoma.